Company Overview of Lotus Tissue Repair, Inc.
Lotus Tissue Repair, Inc. develops recombinant collagen type VII (rC7) technology as a treatment for dermatologic conditions. Its solutions include a protein replacement therapy for the treatment of dystrophic epidermolysis bullosa, a group of genetic skin disease. The company offers its rC7 technology for chronic wound healing, such as diabetic foot ulcers, venous stasis ulcers, and similar conditions. Lotus Tissue Repair, Inc. was incorporated in 2010 and is based in Cambridge, Massachusetts. As of February 12, 2013, Lotus Tissue Repair, Inc. operates as a subsidiary of Shire plc.
One Mifflin Place
Cambridge, MA 02138
Founded in 2010
Key Executives for Lotus Tissue Repair, Inc.
Similar Private Companies By Industry
|Leptogen, Inc.||United States|
|Glycostasis, Inc.||United States|
|ArmaGen Technologies, Inc.||United States|
|Applied Veterinary Systems||United States|
|Orthogonal Diagnostics, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Lotus Tissue Repair, Inc., please visit www.lotustissuerepair.com. Company data is provided by Capital IQ. Please use this form to report any data issues.